NCT02344303View on ClinicalTrials.gov

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

TRV130

DRUG

Moxifloxacin

DRUG

Placebo

Trial Locations (1)

21225

Baltimore

All Listed Sponsors
lead

Trevena Inc.

INDUSTRY

NCT02344303 - Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals | Biotech Hunter | Biotech Hunter